Oncology News | pharmaphorum

News

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.

News

Roche looks to Astex in $515m breast cancer deal

Roche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.

News

Novartis snaps up UK ADC developer Myricx Bio

Novartis has reached a deal to buy Myricx Bio for up to $1.5bn, giving it control of the London, UK, start-up's ADC platform.

News

Olympic cyclist Chris Hoy praises cancer charity campaign

Sir Chris Hoy has said he is proud of participants in the Tour de 4 cycling event he set up last year to change perceptions of stage 4 cancer.

News

Roche's KRAS drug tops its rivals in lung cancer trial

Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new phase 3 data for its experimental KRAS G12C inhibitor, divarasib.

News

FDA clears Orca's cell therapy Tregzi for GvHD

Orca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants.

NICE aims to cut funding for Amgen lung cancer drug Lumykras

Roche looks to Astex in $515m breast cancer deal

Novartis snaps up UK ADC developer Myricx Bio

Olympic cyclist Chris Hoy praises cancer charity campaign

Roche's KRAS drug tops its rivals in lung cancer trial

FDA clears Orca's cell therapy Tregzi for GvHD

ASCO 2026: All about DNA damage response, with Luke Piggot

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks